

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Medical technologies evaluation programme

### Equality impact assessment: Guidance

#### GID-MT582 Kurin Lock for blood culture collection

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

#### Medical technology draft guidance document

1. Have any potential equality issues been identified during the scoping process been addressed by the committee, and, if so, how?

Kurin Lock is a device for collecting blood that is then cultured to check for the presence of bloodstream infections including sepsis. Infants (under 1 year of age), older people (over 75 years of age), people who are immunocompromised (such as people undergoing cancer treatment) and women who are pregnant, post-partum, or have had a termination of pregnancy or miscarriage in the past six weeks are at an increased risk of developing sepsis. People with a learning disability or people who have difficulty communicating may also be at an increased risk. Age, disability and pregnancy and maternity are protected characteristics under the Equality Act 2010.

The company state that Kurin Lock can be used in people of all ages. No equality issues were identified during the scoping process in relation to use of Kurin Lock.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No.

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

No.

**Approved by Associate Director: Anastasia Chalkidou**

**Date: 12/10/2023**

## Medical technology guidance document

- 1.** Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues were raised.

- 2.** If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations did not change after consultation.

- 3.** If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable.

- 4.** If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

**5.** Have the committee’s considerations of equality issues been described in the medical technology guidance document, and, if so, where?

No because no equality issues were raised

**Approved by Programme Director:** Sarah Byron

**Date:** 19/03/24